Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Blood
|
December 23, 1999
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
F Dazzi, R M Szydlo, C Craddock, et al.
British Journal of Haematology
|
December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
T I Mughal, A Yong, R M Szydlo, et al.
Blood
|
December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group
A Hochhaus, A Reiter, S Saussele, et al.
Leukemia
|
February 11, 2005
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse
D Marin, J Kaeda, R Szydlo, et al.
Leukemia
|
March 16, 2007
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy
M P Simula, S Marktel, C Fozza, et al.
Human Heredity
|
May 1, 1996
Molecular characterization of erythrocyte glucose-6-phosphate dehydrogenase deficiency in Al-Ain District, United Arab Emirates
R A Bayoumi, M S Nur-E-Kamal, M Tadayyon, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Blood
|
December 23, 1999
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
F Dazzi, R M Szydlo, C Craddock, et al.
British Journal of Haematology
|
December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
T I Mughal, A Yong, R M Szydlo, et al.
Blood
|
December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group
A Hochhaus, A Reiter, S Saussele, et al.
Leukemia
|
February 11, 2005
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse
D Marin, J Kaeda, R Szydlo, et al.
Leukemia
|
March 16, 2007
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy
M P Simula, S Marktel, C Fozza, et al.
Human Heredity
|
May 1, 1996
Molecular characterization of erythrocyte glucose-6-phosphate dehydrogenase deficiency in Al-Ain District, United Arab Emirates
R A Bayoumi, M S Nur-E-Kamal, M Tadayyon, et al.
Page
of 3